0001209191-21-026742.txt : 20210414 0001209191-21-026742.hdr.sgml : 20210414 20210414200013 ACCESSION NUMBER: 0001209191-21-026742 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210412 FILED AS OF DATE: 20210414 DATE AS OF CHANGE: 20210414 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tomasi Adam CENTRAL INDEX KEY: 0001637219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38582 FILM NUMBER: 21826991 MAIL ADDRESS: STREET 1: ZS PHARMA, INC. STREET 2: 508 WRANGLER DRIVE, SUITE 100 CITY: COPPELL STATE: TX ZIP: 75019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allakos Inc. CENTRAL INDEX KEY: 0001564824 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454798831 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 975 ISLAND DRIVE STREET 2: SUITE 201 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-597-5002 MAIL ADDRESS: STREET 1: 975 ISLAND DRIVE STREET 2: SUITE 201 CITY: REDWOOD CITY STATE: CA ZIP: 94065 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-12 0 0001564824 Allakos Inc. ALLK 0001637219 Tomasi Adam 975 ISLAND DRIVE, SUITE 201 REDWOOD CITY CA 94065 0 1 0 0 President, COO and CFO Common Stock 2021-04-14 4 S 0 20000 107.77 D 153126 D Common Stock 2021-04-14 4 M 0 20000 0.6875 A 173126 D Common Stock 2021-04-13 4 S 0 20000 103.08 D 153126 D Common Stock 2021-04-13 4 M 0 20000 0.6875 A 173126 D Common Stock 2021-04-12 4 S 0 20000 104.40 D 153126 D Common Stock 2021-04-12 4 M 0 20000 0.6875 A 173126 D Common Stock 3953 I See footnote Stock Option (Right to buy) 0.6875 2021-04-14 4 M 0 20000 0.00 D 2027-05-17 Common Stock 20000 586400 D Stock Option (Right to buy) 0.6875 2021-04-13 4 M 0 20000 0.00 D 2027-05-17 Common Stock 20000 606400 D Stock Option (Right to buy) 0.6875 2021-04-12 4 M 0 20000 0.00 D 2027-05-17 Common Stock 20000 626400 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. This transaction was executed in multiple trades at prices ranging from $103.62 to $108.86 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price. Includes shares of common stock purchased under the Company's 2018 Employee Stock Purchase Plan. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. This transaction was executed in multiple trades at prices ranging from $101.43 to $105.55 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. This transaction was executed in multiple trades at prices ranging from $102.19 to $106.17 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price. Includes 3,953 shares received as a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners Management VIII, LLC (APM VIII), without consideration, to the reporting person as a non-managing member of APM VIII. The shares are held by Mr. Tomasi and Carrie Tomasi, as Trustees of the Tomasi Living Trust dated July 14, 2017. On May 17, 2017, the Reporting Person was granted an option to purchase 706,400 ordinary shares pursuant to the Company's 2012 Equity Incentive Plan. The option vests as to one-fourth of the shares on May 17, 2018, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. /s/ Adam Tomasi 2021-04-14